Stereotaxis Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY Revenue (est.)
$39.4Mnext fiscal year
FY EPS (est.)
-$0.19next fiscal year
Monitoring Framework
Key Performance Indicators
Annual Revenue Annually31.2MTarget: Surpass $40 million in FY 2026
Quarterly Revenue Quarterly6.3MTarget: Exceed $10 million per quarter in Q3 and Q4 2026
System Revenue Gross Margin Quarterly39.0%
Recurring Revenue Gross Margin Quarterly66.0%
Watch Items
- MAGiC Catheter Manufacturing Scale-upTrigger: Supply constraints failing to meet high demand in Europe and the USAction: Monitor sequential revenue growth and manufacturing capacity updates in quarterly earnings calls
- Integration of Robocath AcquisitionTrigger: Execution of definitive agreement to acquire RobocathAction: Track regulatory approvals, product integration milestones, and cash burn impact
- Winding down of Johnson & Johnson relationshipTrigger: Headwinds on recurring revenue due to transition away from legacy J&J cathetersAction: Evaluate if proprietary MAGiC catheter adoption rate offsets the J&J revenue decline
Research as of 20 Jun 2026